...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Tonic inhibition by G Protein-Coupled receptor Kinase 2 of Akt/Endothelial Nitric-Oxide synthase signaling in human vascular endothelial cells under conditions of Hyperglycemia with high insulin levels
【24h】

Tonic inhibition by G Protein-Coupled receptor Kinase 2 of Akt/Endothelial Nitric-Oxide synthase signaling in human vascular endothelial cells under conditions of Hyperglycemia with high insulin levels

机译:高胰岛素高血糖条件下人血管内皮细胞中G蛋白偶联受体激酶2对Akt /内皮型一氧化氮合酶信号的抑制作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

G protein-coupled receptor kinase 2 (GRK2) participates together with b-Arrestins in the regulation of G protein-coupled receptor signaling, but emerging evidence suggests that GRK2 can interact with a growing number of proteins involved in signaling mediated by other membrane receptor families under various pathologic conditions. We tested the hypothesis that GRK2 may be an important contributor to vascular endothelial dysfunction in diabetes. Human umbilical venous endothelial cells (HUVECs) were exposed to high glucose and high insulin (HG/HI) to mimic insulin-resistant diabetic conditions. GRK2 expression and membrane translocation were up-regulated under HG/HI conditions. HG/HI did not modify activation of Akt or endothelial nitric-oxide synthase (eNOS), but GRK2 inhibitor or small interfering RNA (siRNA) resulted in an increase in Akt and eNOS activation in HUVECs exposed to HG/HI. Extracellular signal-regulated kinase 1/2 (ERK1/2) activation was increased after exposure to HG/HI, which was prevented by GRK2 inhibitor or siRNA. ERK1/ 2-mediated GRK2 phosphorylation at Ser-670 confirmed that ERK1/2 participated in a negative feedback regulatory loop. In human embryonic kidney 293T cells that overexpressed GRK2, Akt activity was unchanged, whereas ERK1/2 activity was raised. The effect of GRK inhibitor treatment on Akt/eNOS signaling was associated with membrane translocation of b-Arrestin 2. The experiments with b-Arrestin 2 siRNA showed that b-Arrestin 2 may act as a positive modulator of Akt/eNOS signaling. Our studies reveal that GRK2, which is up-regulated by HG/HI, leads to a tonic inhibition of the insulin Akt/eNOS pathway in endothelial cells. We provide new insights into the pathogenesis of diabetes-Associated vascular endothelial dysfunction.
机译:G蛋白偶联受体激酶2(GRK2)与b-Arrestins一起参与G蛋白偶联受体信号传导的调节,但新兴证据表明GRK2可以与越来越多的蛋白质相互作用,这些蛋白质参与其他膜受体家族介导的信号传导在各种病理条件下我们检验了GRK2可能是糖尿病血管内皮功能障碍的重要因素的假设。将人脐静脉内皮细胞(HUVEC)暴露于高葡萄糖和高胰岛素(HG / HI)中,以模拟胰岛素抵抗性糖尿病。 GRK2表达和膜易位在HG / HI条件下上调。 HG / HI不会改变Akt或内皮一氧化氮合酶(eNOS)的激活,但是GRK2抑制剂或小的干扰RNA(siRNA)导致暴露于HG / HI的HUVEC中Akt和eNOS激活增加。暴露于HG / HI后,细胞外信号调节激酶1/2(ERK1 / 2)激活增加,这被GRK2抑制剂或siRNA阻止。 ERK1 / 2介导的GRK2在Ser-670的磷酸化证实ERK1 / 2参与了负反馈调节环。在过度表达GRK2的人胚肾293T细胞中,Akt活性未改变,而ERK1 / 2活性却升高。 GRK抑制剂治疗对Akt / eNOS信号的影响与b-Arrestin 2的膜易位有关。用b-Arrestin 2 siRNA进行的实验表明,b-Arrestin 2可以作为Akt / eNOS信号的正调节剂。我们的研究表明,由HG / HI上调的GRK2导致内皮细胞中胰岛素Akt / eNOS途径的强直抑制。我们提供有关糖尿病相关血管内皮功能障碍的发病机制的新见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号